BIRMINGHAM, Alabama (August 19, 2021)—A surge in demand for sleep and respiratory devices in the wake of a Philips Respironics recall has created “an unprecedented increase in demand” for Resmed devices, the company’s CEO said—but supply chain and freight limitations are making it hard for the company to keep up. Nonetheless, the company could realize $300 million-$350 million in unplanned additional revenue in fiscal year 2022, he said.

SAN DIEGO (August 16, 2021)—ResMed, a provider of digital health and sleep apnea treatment, launched AirSense 11, available first in the United States, the company’s next-generation PAP (positive airway pressure) device designed to help hundreds of millions of people worldwide with sleep apnea start and stay on therapy to treat and manage obstructive sleep apnea.

WASHINGTON, D.C. (February 26, 2021)—ResMed’s Vice President of Global Government Affairs and Market Access, Larissa D’Andrea, has accepted the open position on the Executive Committee for AAHomecare. The open position became available following another merger within the industry, and the association reached out to the talented and committed advocate to fill the position. D’Andrea most recently sat on the board of directors for the association.



SAN DIEGO (October 22, 2019) ResMed introduced AirFit N30, a tube-down nasal cradle CPAP mask with a front-facing tub—a new option for sleep apnea treatment.

ResMed’s lightest mask yet, AirFit N30 features an adjustable elastic headgear, plus a nasal cradle cushion that sits under the nasal bridge, eliminating soreness in that area. The mask’s curved cushion is designed to provide a secure seal regardless of how the wearer sleeps or moves.


BOSTON (September 24, 2019)—ResMed has been named the 2019 “Dealmaker of the Year” by Medtech Insight, an award that recognizes the company most adept at advancing its business through investment deals. The award was presented Monday night by Medtech Insight owner Pharma Intelligence, a leading global analyst firm serving the pharmaceutical, medical device, and clinical research industries.